Multimodality Imaging Assessment of Ocular Ischemic Syndrome
Table 2
Clinical presentation of the two groups.
OIS
Control
value
Number of patients (n)
30
30
Vision loss, n (%)
27 (90.00%)
8 (26.67%)
Ocular pain, n (%)
11 (36.67%)
2 (6.67%)
Visual field defect, n (%)
12 (40.00%)
0 (0.00%)
Baseline BCVA (LogMAR)
0.30 ± 0.16
0.17 ± 0.15
Refractive error (SE)
−0.88 (−1.56, −0.50)
−0.75 (−1.25, 0.00)
†
IOP (mmHg, mean ± SD)
19.41 ± 4.91
13.91 ± 2.52
Anterior segment signs
22
3
‡
Corneal edema
6 (20.00%)
2 (6.67%)
‡
Episcleral injection
8 (26.67%)
0 (0.00%)
‡
Anterior uveitis (flare, cells, KP)
8 (26.67%)
0 (0.00%)
‡
INV
22 (73.33%)
1 (3.33%)
‡
NVG
10 (33.33%)
0 (0.00%)
‡
Uveitis
2 (6.67%)
0 (0.00%)
‡
Posterior segment signs
24
10
‡
Narrowed RA
19 (63.33%)
3 (10.00%)
‡
Dilated RV
19 (63.33%)
4 (13.33%)
‡
Retinal haemorrhages
15 (50.00%)
6 (20.00%)
‡
Microaneurysms
21 (70.00%)
5 (16.67%)
‡
BCVA: best-corrected visual acuity; SE: spherical equivalent; IOP: intraocular pressure; RA: retinal artery; RV: retinal vein; INV: iris neovascularisation; NVG: neovascular glaucoma; NVD: neovascularization of disc; NVE: neovascularization of retina elsewhere. values were calculated using the independent t-test. values were calculated using the Mann–Whitney U test. ‡Fisher’s exact test of chi-square tests.
